Cantor Fitzgerald Comments on RCKT FY2025 Earnings

Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT) – Equities researchers at Cantor Fitzgerald issued their FY2025 earnings per share estimates for Rocket Pharmaceuticals in a research note issued on Tuesday, January 21st. Cantor Fitzgerald analyst J. Schimmer forecasts that the biotechnology company will post earnings of ($3.20) per share for the year. Cantor Fitzgerald currently has a “Overweight” rating and a $65.00 target price on the stock. The consensus estimate for Rocket Pharmaceuticals’ current full-year earnings is ($2.83) per share.

Several other analysts also recently issued reports on RCKT. Chardan Capital reissued a “buy” rating and set a $62.00 target price on shares of Rocket Pharmaceuticals in a research note on Monday, November 18th. Needham & Company LLC reaffirmed a “buy” rating and set a $52.00 target price on shares of Rocket Pharmaceuticals in a research note on Tuesday, November 19th. Leerink Partners reduced their price target on shares of Rocket Pharmaceuticals from $46.00 to $44.00 and set an “outperform” rating for the company in a research report on Tuesday, November 19th. Jefferies Financial Group initiated coverage on shares of Rocket Pharmaceuticals in a report on Wednesday, December 18th. They set a “buy” rating and a $29.00 price target for the company. Finally, Wedbush initiated coverage on shares of Rocket Pharmaceuticals in a research note on Monday, December 30th. They set an “outperform” rating and a $32.00 target price for the company. One research analyst has rated the stock with a sell rating, one has issued a hold rating and eleven have given a buy rating to the company. According to data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus target price of $47.27.

Rocket Pharmaceuticals Stock Up 5.7 %

Shares of NASDAQ:RCKT opened at $11.08 on Thursday. The firm has a 50 day simple moving average of $12.39 and a 200 day simple moving average of $16.88. Rocket Pharmaceuticals has a 52 week low of $10.07 and a 52 week high of $31.47. The company has a debt-to-equity ratio of 0.06, a quick ratio of 6.05 and a current ratio of 6.05. The company has a market cap of $1.01 billion, a PE ratio of -4.03 and a beta of 1.01.

Rocket Pharmaceuticals (NASDAQ:RCKT) last posted its quarterly earnings data on Thursday, November 7th. The biotechnology company reported ($0.71) EPS for the quarter, beating analysts’ consensus estimates of ($0.78) by $0.07.

Institutional Inflows and Outflows

Institutional investors have recently bought and sold shares of the company. Novo Holdings A S grew its position in shares of Rocket Pharmaceuticals by 4.8% in the second quarter. Novo Holdings A S now owns 1,100,000 shares of the biotechnology company’s stock valued at $23,683,000 after purchasing an additional 50,000 shares during the last quarter. Renaissance Technologies LLC acquired a new position in Rocket Pharmaceuticals during the 2nd quarter valued at $2,144,000. Mirador Capital Partners LP boosted its holdings in Rocket Pharmaceuticals by 403.9% in the 4th quarter. Mirador Capital Partners LP now owns 84,529 shares of the biotechnology company’s stock valued at $1,063,000 after purchasing an additional 67,755 shares during the period. First Turn Management LLC grew its position in Rocket Pharmaceuticals by 10.8% in the 3rd quarter. First Turn Management LLC now owns 621,306 shares of the biotechnology company’s stock worth $11,476,000 after purchasing an additional 60,317 shares during the last quarter. Finally, Walleye Capital LLC bought a new position in shares of Rocket Pharmaceuticals during the 3rd quarter worth about $2,556,000. Institutional investors own 98.39% of the company’s stock.

Insider Transactions at Rocket Pharmaceuticals

In other news, CEO Gaurav Shah sold 11,091 shares of the business’s stock in a transaction on Thursday, November 21st. The shares were sold at an average price of $13.05, for a total value of $144,737.55. Following the completion of the sale, the chief executive officer now directly owns 707,328 shares in the company, valued at approximately $9,230,630.40. The trade was a 1.54 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. In the last quarter, insiders sold 13,490 shares of company stock worth $176,045. 28.50% of the stock is owned by corporate insiders.

About Rocket Pharmaceuticals

Rocket Pharmaceuticals, Inc, together with its subsidiaries, operates as a late-stage biotechnology company that focuses on developing gene therapies for rare and devastating diseases. It has three clinical-stage ex vivo lentiviral vector programs for fanconi anemia, a genetic defect in the bone marrow that reduces production of blood cells or promotes the production of faulty blood cells; leukocyte adhesion deficiency-I, a genetic disorder that causes the immune system to malfunction; and pyruvate kinase deficiency, a rare red blood cell autosomal recessive disorder that results in chronic non-spherocytic hemolytic anemia.